



Multimeric

Multimeric Biotherapeutics, Inc.

Multimeric Biotherapeutics Selected as a Semi-Finalist in PitchFest VC Competition

SAN DIEGO, November 7, 2012 – Multimeric Biotherapeutics, Inc., a biopharmaceutical company developing its proprietary super ligands for the treatment of cancer and infectious diseases, today announced that it had been selected as a semi-finalist in the annual [PitchFest](#) competition conducted by the [San Diego Venture Group \(SDVG\)](#). Out of over 110 applicant companies, Multimeric was one of only eleven selected to be a semi-finalist. If selected in a further round of screening, the company would go on to present to the San Diego investment community at a gala dinner event on December 13, 2012.

“It is an honor to have been selected as a semi-finalist by SDVG’s eminent panel of judges,” stated Richard Kornbluth, M.D., Ph.D., Multimeric’s president and chief scientific officer. “This reflects well on the strength of our investment opportunity and the extraordinary promise of our MegaLigand™ and UltraLigand™ technology.”

About MegaLigands™

MegaLigands are 2-trimer forms of the tumor necrosis factor super family (TNFSF) ligands produced by fusing the extracellular domains of any of the 19 members of the TNF SuperFamily with a scaffold protein consisting of the body of ACRP30 (adiponectin). The following molecules are currently sold as purified proteins for laboratory use: MegaCD40L™; MegaTNF™; MegaOX40L™; and MegaAPRIL™. MegaCD40L™ in particular has been used extensively by academic investigators as a vaccine adjuvant and cancer immunotherapy agent.

About UltraLigands™

UltraLigands are 4-trimer forms of the TNFSF ligands produced by fusing the extracellular domains of any of the 19 members of the TNF SuperFamily with a scaffold protein consisting of the body of surfactant protein D (SP-D). UltraCD40L™ has been shown to be a powerful adjuvant for DNA vaccines as well as an effective cancer immunotherapy in mouse models. A recently published study in the journal *Vaccine* demonstrated the versatility of this platform technology by reporting applications for the following UltraLigands™ as adjuvants for DNA vaccines: UltraCD40L™; UltraGITRL™; Ultra4-1BBL™; UltraOX40L™; UltraRANKL™; UltraLIGHT™; UltraCD70™; and UltraBAFF™.

About Multimeric

Multimeric Biotherapeutics, Inc. was formed around technology invented by Dr. Richard Kornbluth when he was at the University of California San Diego. Multimeric’s lead product is MegaCD40L™, a highly active form of CD40 ligand (CD40L), which is the strongest immune stimulator made by the body. MegaCD40L™ is being developed to treat cancer and power new vaccines. The company has received funding from its founders, angel investors, and NIH grants. It operates out of fully equipped laboratory space in the San Diego Science Center. For more information, please visit the company website at www.multimericbio.com